ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 355

The Clinical and Genetic Spectrum of Low Alkaline Phosphatase in Adults

Leyre Riancho-Zarrabeitia1, Maria T. García-Unzueta2, Jair A. Tenorio3, Juan Gómez-Gerique4, Víctor L Ruiz Pérez3, Karen E. Heath3, Pablo Lapunzina3 and José A. Riancho5, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, 2Biochemistry, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, 3Institute of Medical and Molecular Genetics. Hospital U. La Paz. IdiPAZ. Autonomous University of Madrid. CIBERER., Madrid, Spain, 4Biochemistry, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, 5Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. University of Cantabria, Santander, Spain

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Bisphosphonates, Bone, bone disease and genetic disorders

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Osteoporosis and Metabolic Bone Disease - Clinical Aspects and Pathogenesis Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Different from infantile forms, adult forms of hypophosphatasia have less severe manifestations and may go unrecognized. Low serum levels of alkaline phosphatase (ALP), the enzyme encoded by the ALPL gene, are a hallmark of hypophosphatasia. However, the clinical significance and the underlying genetics of low ALP in unselected populations are unclear. 

Methods:

In order to clarify this issue, we performed a clinical and biochemical study of subjects with reduced serum ALP activity. The screening of the coding sequences and intron/exon boundaries of ALPL gene was performed by direct sequencing using the BrightDye Terminator cycle kit.    

Results:

Forty two adult individuals with unexplained persistently low serum ALP were studied. There was a 3:1 female:male ratio. Age range was 20-77 yr.  Although many subjects experienced minor complains, such as mild musculoskeletal pain (60%), none had major health problems. ALPL mutations were found in 21 out of 42 subjects (50%). Twenty patients carried heterozygous mutations; whereas 1 had a homozygous mutation. Eight mutations were novel and had not been previously described. Eighteen of the 21 patients with mutations (86%) had a missense mutation; in 1 case the mutation caused a splice change and there were 2 frameshift mutations. Most mutations were located in exons 5 and 6 (12 aminoacid positions were mutated in 17 patients) and were predicted to have a damaging effect on the protein activity, both according to the structure-based Polyphen webtool (13 mutations) and the evolutionary criteria proposed by Silvent (14 mutations). The presence of a mutated allele was associated with premature tooth loss (48% versus 12%; p=0.04), slightly lower levels of serum AP (30±6 vs 25±6 u/l; p=0.002) and higher levels of enzyme substrates, such as serum pyridoxal phosphate (p<0.0001) and urine phosphoetanolamine (p<0.0001), as well as mildly increased serum phosphate (p=0.03). Ten patients had pyridoxal phosphate levels above the normal range, a test frequently used when hypophosphatasia is suspected. All carried a gene mutation; predicted to be deleterious in 9 cases and of doubtful significance in one.  

Conclusion: One  half of adults with persistently low levels of total alkaline phosphatase had a mutated allele of the ALPL gene. Although clinical manifestations are usually mild, in about 50% of them enzyme activity is low enough to cause substrate accumulation and may predispose to disorders of the teeth and other calcified tissues.


Disclosure: L. Riancho-Zarrabeitia, None; M. T. García-Unzueta, None; J. A. Tenorio, None; J. Gómez-Gerique, None; V. L. Ruiz Pérez, None; K. E. Heath, None; P. Lapunzina, None; J. A. Riancho, None.

To cite this abstract in AMA style:

Riancho-Zarrabeitia L, García-Unzueta MT, Tenorio JA, Gómez-Gerique J, Ruiz Pérez VL, Heath KE, Lapunzina P, Riancho JA. The Clinical and Genetic Spectrum of Low Alkaline Phosphatase in Adults [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/the-clinical-and-genetic-spectrum-of-low-alkaline-phosphatase-in-adults/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-clinical-and-genetic-spectrum-of-low-alkaline-phosphatase-in-adults/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology